Iantrek completed $42 million Series C Round funding
Sector:
MedTech
08/20/2025
White Plains, NY USA
Iantrek
completed $42 million Series C Round funding. Investors include
USVP (lead), aMoon Fund, Visionary Ventures, Sectoral Asset Management, JSD Capital, Civilization Ventures.
“Our mission is to address a major unmet need in glaucoma care, and this fundraise marks a pivotal moment in helping us achieve it,” said Adam Szaronos, CEO of Iantrek. “More than 2.5 million eyes in the U.S. are experiencing waning efficacy from previous Minimally Invasive Glaucoma Surgery (MIGS) procedures targeting the trabecular pathway. AlloFlo™ Uveo enables access to the uveoscleral pathway, the eye’s other natural drainage system—much like giving a thoracic surgeon the ability to enhance the second lung.”
About
Founded by ophthalmic innovator Sean Ianchulev, MD, MPH, Iantrek is a venture-funded medical technology company pioneering bio-interventional and micro-interventional products for ophthalmic surgery. The company’s portfolio includes AlloSert™ Uveo, AlloFlo™ Uveo, CanaloFlo™, and C.Rex™— bio-interventional and micro-interventional solutions for the management of glaucoma.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
